In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Virpax Pharmaceuticals (VRPX – Research Report), with a price target of $4.00. The company’s shares opened today at $1.05.
Rahman covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Neurosense Therapeutics Ltd., and Processa Pharmaceuticals. According to TipRanks, Rahman has an average return of -10.0% and a 35.71% success rate on recommended stocks.
Virpax Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
VRPX market cap is currently $12.89M and has a P/E ratio of -0.57.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.
Read More on VRPX:
